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Abstract
Introduction: Beta-propeller protein associated neurodegeneration (BPAN) is associated with mutations in the WD
repeat domain 45 (WDR45) gene on chromosome Xp11 resulting in reduced autophagic flux. This study describes the
clinical and neuropathological features of a female 51 year old BPAN case. The clinical history includes learning disability
and progressive gait abnormalities since childhood followed by progressive dystonic features in young adulthood. Brain
imaging revealed generalised brain atrophy and bilateral mineralisation of the globus pallidus and substantia nigra.
Results: The major pathological findings were observed in the substantia nigra with excess iron deposition, gliosis,
axonal swellings and severe neuronal loss. Iron deposition was also observed in the globus pallidus. There was extensive
hyperphosphorylated-tau deposition in the form of neurofibrillary tangles, pre-tangles and neuropil threads. Furthermore,
histological studies and immunoblotting confirmed a mixed Alzheimer type 3-and 4-repeat tau pathology.
Microtubule-associated protein 1A/1B-light chain 3 (LC3) immunoblotting of brain homogenates indicated autophagic
activity and may support the role of WDR45 in autophagy.
Conclusions: The widespread Alzheimer-type tau pathology in this disease indicates that this should be considered as
a tauopathy and adds further support to the proposal that impaired autophagy may have a role in tauopathies.
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Introduction
The dysregulation of brain iron metabolism leading to
accumulation of iron in the basal ganglia and substantia
nigra is a characteristic feature of the group of inherited
neurological disorders classified under the term neuro-
degeneration with brain iron accumulation (NBIA). The
main clinical features of NBIA include progressive dystonia,
dysarthia, spasticity, parkinsonism and optic atrophy. The
age of onset and rate of progression of the disease varies.
Several genetic forms have been identified: pantothenate
kinase-associated neurodegeneration (PKAN) with muta-
tions in pantothenate kinase 2 (PANK2); PLA2G6-asso
ciated neurodegeneration (PLAN) due to mutations in
phospholipase A2, group VI (PLA2G6), fatty-acid hydroxy
lase-associated neurodegeneration (FAHN) associated with
mutations in fatty acid 2-hydroxylase (FA2H), mitochon-
drial membrane protein-associated neurodegeneration
(MPAN) due to mutations in chromosome 19 open reading
frame 12 (C19orf12), Kufor-Rakeb-Syndrome (KRS) due to
ATPase type 13A2 (ATP13A2), aceruloplasminemia due to
mutations in ceruloplasmin (CP), hereditary neuroferri-
tinopathy due to mutations in ferritin-L subunit gene
FTL1, Coasy protein-associated neurodegeneration as-
sociated with mutations in bifunctional coenzyme A
synthase (COASY) and Woodhouse-Sakati-Syndrome
(WSS) due to mutations in DCAF17 [1, 2]. The muta-
tions associated with different forms of NBIA involve a
variety of metabolic pathways. PKAN, PLA2G6, COASY
and FA2H have roles in fatty acid metabolism, C19orf12
encodes a protein with a role in mitochondrial function
and fatty acid metabolism. CP and FTL1 have functions
in iron homeostasis, DCAF17 regulates transcription
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Recently de novo mutations in the gene encoding WD
repeat containing protein 45 (WDR45) have been associ-
ated with an X-linked dominant form of NBIA causing
static encephalopathy of childhood with neurodegenera-
tion in adulthood (SENDA), now reclassified as BPAN
(β-propeller protein-associated neurodegeneration), or
NBIA5 [3–5]. Clinical manifestations include global de-
velopmental delay with intellectual disability in infancy
or early childhood followed by further neurological and
cognitive decline in adolescence with progressive dystonia,
parkinsonism, ocular defects and sleep perturbation [3, 5].
During the course of clinical deterioration, iron accumula-
tion involving the substantia nigra and globus pallidus is
evident as observed in brain imaging [5]. WDR45 encodes
a beta-propeller scaffold protein which has a role in au-
tophagy and autophagic flux has been found to be reduced
in lymphoblasts from BPAN patients [4, 6].
The neuropathological description of a previously re-
ported case with mutation in WDR45 demonstrated the
hallmark feature of NBIA, with iron accumulation in the
substantia nigra and in the globus pallidus together with
axonal spheroids, gliosis and severe neuronal loss. In the
cerebellum significant depletion of Purkinje cells with
axonal torpedoes was observed. Tau positive neurofibrillary
tangles (NFTs) were described in several brain regions [5].
We report the detailed neuropathological description
of a case with the previously reported loss-of-function
mutation, p.Leu232Alafs*53 in WDR45 [3, 5]. Tau path-
ology has been analysed using immunohistochemistry
(IHC) and immunoblotting. We have also investigated




The brain was donated to the Queen Square Brain Bank
for neurological disorders (QSBB) where all cases are
collected for research according to ethically approved
protocols and are stored under a licence from the Human
Tissue Authority. The left half of the brain was fixed in
10 % neutral buffered formalin before being dissected in
the coronal plane, examined and blocks selected for paraf-
fin wax embedding and histology.
Paraffin-embedded sections (8 μm) were cut and stained
using routine histological methods. Sections were stained
using haematoxylin and eosin (H&E), Gallyas silver and
Luxol fast blue/cresyl violet. IHC staining was performed
using an avidin-biotin complex protocol using the anti-
bodies and pre-treatments detailed in Additional file 1:
Table S1. Antibody binding sites were visualized using the
chromogen diaminobenzidine and sections were counter-
stained using Mayer’s haematoxylin.
Neuronal loss was assessed on H&E stained sections
and scored semi-quantitatively (− = none; + =mild; ++ =
moderate; +++ = severe). Tau pathology was assessed
using AT8 antibody and the tau burden was scored
semi-quantitatively for tau positive neuropil threads,
pre-tangles and NFTs (− = none; + = infrequent; ++ =
moderate; +++ = frequent).
Immunoblotting
Tau
Sarkosyl-insoluble tangle PHF-tau was isolated from brain
samples as previously described [7]. Insoluble PHF-tau
was enriched from frontal cortex of the WDR45 case. As
controls, a case each of Alzheimer’s disease (AD) and
Pick’s disease (PiD) were selected from the archive of the
QSBB [8, 9]. The homogenate was denatured in NuPage®
LDS Sample buffer (Invitrogen, UK) at 70 °C for 10 min
and loaded onto a 4–12 % Bis-Tris gel (Invitrogen, UK).
The protein was then transferred onto nitrocellulose
membrane (Amersham) and the membrane was incubated
with antibody against tau (rabbit polyclonal, Dako) over-
night at 4 °C followed by incubation for 1 h with an appro-
priate fluorescent secondary antibody and analysed using
an Odyssey scanner (Licor).
Autophagosome associated light chain 3 (LC3)
Samples of frontal cortex from the WDR45 case and
three age and sex matched controls selected from the
archive of the QSBB were homogenised in 50 mM Tris–
HCl pH7.5, 150 mM NaCl, 5 mM EDTA, 1 % tritonX-
100, 2 % SDS containing complete protease inhibitor
and phosphatase inhibitor (Roche). Tissue lysates were
obtained after centrifugation of homogenised samples at
10000 g for 15 min. Protein concentration was deter-
mined using Bio-RAD protein assay kit. Protein lysates
(40 μg) were analysed by SDS-PAGE on 4–12 % Bis-Tris
gel (Nupage, Invitrogen) and transferred onto nitrocellu-
lose membranes (Amersham). Membranes were blocked
in 5 % BSA in phosphate buffered saline-tween for 1 h at
room temperature, before being probed overnight at 4 °C
with LC3 and beta-actin primary antibodies. The following
steps of the protocol were as described above. The immu-
noblots were repeated twice with similar results.
Results
Clinical details
The female patient had learning difficulties as a child
with progressive gait abnormalities. In school, other chil-
dren would tease her for her “funny gait” as well as for
being unable to keep up in class. By the age of 13, she
moved to a special school for handicapped children. At
age 19, she left school and continued to live in a specia-
lised community for mentally and physically challenged
people. Due to increasing behavioural difficulties at age
36 she moved to a social service hostel from where she
attended a day centre several times a week.
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Her movement disorder symptoms started deteriorating
significantly at the age of 29 with slowing of gait and re-
duction of arm-swing whilst walking. Even though there
were initial doubts in the diagnosis of Parkinson’s disease,
she was started on Pergolide and later on Levodopa, both
with equivocal and unpredictable effects with the subse-
quent development of dyskinesias and severe fluctuation
of mobility. She deteriorated rapidly and developed dys-
tonic features with an inward turning of the left foot, a
bilateral akinetic-rigid syndrome with orofacial stereo-
typies during her thirties. Due to increasing behavioural
problems, social withdrawal, reduced attention span and
motivation a combination of cognitive and behavioural
therapy was started in 1998. She was treated with Sertra-
line, and later with Amitriptyline, Velofaxine, Slisulpiride,
and Carbamazepine, all with little effect. She had dis-
turbed sleep with early morning awakening and behav-
ioural problems with long off-phases. In the later stages of
the disease she was wheelchair-bound and had urinary
and faecal incontinence.
Other medical problems included slowly evolving diffi-
culties with her eyesight with intermittent double-vision.
She had a right corneal graft at the age of 32 – unfortu-
nately no detailed further information on the underlying
pathology of this was available. There was no family his-
tory except her mother who received a diagnosis of bipo-
lar disorder and schizophrenia and died of a sudden brain
haemorrhage when the proband was in her twenties.
Brain computerised tomography showed abnormal
bilateral generalised mineralisation of the globus palli-
dus and substantia nigra, likely to represent iron de-
position on subsequent MRI. Other investigations were
normal except for WDR45 gene sequencing which
showed a hemizygous mutation (c.694_703delCTGCG
CCGAG, p.Leu232Alafs*53).
Neuropathology
The fresh brain weighed 1,117 g. External examination
of the left half brain showed frontal atrophy with preser-
vation of parietal, temporal and occipital lobes. Coronal
slices revealed mild dilatation of the frontal horn of the
lateral ventricle and patchy thinning of the cortical rib-
bon in the frontal lobe. In the occipital cortex an area of
cavitation with the appearance of an old infarct involved
the primary visual cortex. The white matter in the anterior
frontal and temporal lobes showed mild atrophy. The
globus pallidus was reduced in size with blurring of the
distinction between internal and external parts and
showed dark discolouration anteriorly (Fig. 1a, arrow).
The caudate and putamen appeared normal. The thal-
amus and hippocampus showed mild atrophy and there
was moderate atrophy of the amygdala. There was marked
abnormality of the substantia nigra which showed brown
discolouration and had a gelatinous texture throughout
(Fig. 1b, double arrow). The locus coeruleus was indis-
cernible (Fig. 1b, arrow). The medulla and cerebellum ap-
peared normal.
Histological examination (Fig. 2) showed mild superfi-
cial vacuolation in the anterior frontal, temporal and
Fig. 1 A coronal slice at the level of the anterior commissure shows
atrophy and dark discolouration of the globus pallidus (a, arrow).
There was loss of pigment in the locus coeruleus which was
indiscernible (b, arrow). The substantia nigra was markedly abnormal
with brown discolouration and a gelatinous texture (b, double arrow)
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parietal cortices. A full thickness cortical infarct with
cavitation, infiltration of macrophages and surrounding
gliosis was confirmed involving the primary visual cortex.
Neuronal loss was mild in neocortical regions (frontal,
temporal, parietal, Table 1) and occasional balloon neu-
rons were identified using a αB-crystallin antibody. Luxol
fast blue staining confirmed good myelin preservation in
the subcortical white matter. There was no cortical iron
deposition identified using Perl’s stain.
Neuronal populations in the hippocampus, amygdala,
striatum, thalamus and subthalamic nucleus were well
preserved. Examination of the globus pallidus showed
extensive mineralisation of vessels including arteries,
veins and capillaries. Perl’s staining for iron was positive
Fig. 2 Histological features in WDR45 mutation. In the substantia nigra there was severe loss of pigmented neurons with gliosis, axonal spheroids
(a) and iron deposition (b). Axonal spheroids were highlighted using immunohistochemical staining for phosphorylated neurofilaments (c, arrow).
There was also extensive iron deposition in the globus pallidus (d). In the frontal cortex there was mild neuronal loss with superficial spongiosis
(e), phosphorylated tau accumulation was abundant in the form of threads and neurofibrillary tangles (f) and there were occasional balloon
neurons. Fibrillar tau in neurofibrillary tangles was demonstrated by argyrophilia (h) and immunohistochemistry using AT100 confirmed the
presence of paired helical filament tau (i). The 3-repeat (j) and 4-repeat (k) tau isoform specific antibodies illustrate the contribution of both
groups of tau isoforms. a & e haematoxylin and eosin; b & d Perl’s stain; c SMI31; f AT8; g αB crystallin; h Gallyas silver impregnation; i AT100;
j 3R tau; k 4R tau. Bar in a represents 200 μm in d & e, 80 μm in a, 40 μm in b, c, f, g & i–k
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Table 1 Summary of neuronal loss and semi-quantitative assessment of tau pathology in different brain regions
Brain regions Neuronal loss Tau pathology
Threads Pre-tangles Neurofibrillary tangles
Cortex
Frontal + +++ - ++
Temporal + +++ - ++
Parietal + +++ - ++
Occipital Infarct visual cortex + - -
Cingulate - +++ - +++
Sub-cortical white matter
Frontal N/A + N/A N/A
Temporal N/A + N/A N/A
Parietal N/A + N/A N/A
Occipital N/A + N/A N/A
Cingulate N/A ++ N/A N/A
Amygdala - +++ - +++
Hippocampus
Dentate fascia - + - ++
CA4 - ++ + ++
CA3 - ++ - ++
CA2 - ++ - ++
CA1 - +++ + +++
Subiculum - +++ + +++
Entorhinal cortex - +++ + +++
Transentorhinal cortex - +++ + +++
Caudate - +++ + ++
Putamen - ++ + ++
Globus pallidus + ++ - +
Meynert + +++ - +++
Thalamus - ++ - ++
Subthalamic nucleus - ++ - ++
Substantia nigra +++ ++ - +
Locus coeruleus + ++ - +
Pontine tegmentum - ++ - ++
Pontine nuclei - + - +
Dorsal motor nucleus of vagus - + - +
Twelfth nerve nucleus - + - -
Inferior olive - + - -
Gracile nucleus - + - -
Cuneate nucleus - + - -
Cerebellar Purkinje cells + - - -
Cerebellar white matter N/A - N/A N/A
Dentate nucleus - + - +
N/A not applicable
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in areas of mineralisation and also in scattered cells with
macrophage morphology. IHC staining for glial fibrillary
acidic protein (GFAP) showed marked gliosis of the
globus pallidus and there was also an increase in CD68-
immunoreactive microglia. No axonal swellings were
identified.
Examination of the midbrain showed very severe loss
of pigmented neurons in the substantia nigra accompan-
ied by gliosis, macrophage infiltration and marked de-
position of Perl’s positive pigment. Numerous axonal
swellings were present and were highlighted with IHC
for amyloid precursor protein (APP), neurofilaments
(neurofilament cocktail, SMI31) and ubiquitin. In the
pons, the locus coeruleus showed mild neuronal loss
with the pontine nuclei being well preserved. In the me-
dulla the Xth and XIIth cranial nerve nuclei as well as
the inferior olivary nucleus were well preserved. Axonal
swellings were observed in the gracile and cuneate nuclei.
The cerebellum showed mild Purkinje cell depletion with
good preservation of the dentate nucleus and hemispheric
myelin. There was no Aβ deposition in the hippocampus
or neocortex. No α-synuclein pathology was found in
brainstem or limbic regions and there was no TDP-43
pathology in limbic structures.
Tau pathology was extensive in the form of NFTs, pre-
tangles and neuropil threads affecting cortical regions,
white matter, deep grey nuclei, hippocampus, amygdala,
brainstem structures and the cerebellum. Very rare
coiled bodies were present in the sub-cortical white matter
but there was no accumulation of tau in astrocytes. The
type of tau pathology and semi-quantitative analysis of the
tau burden in different brain regions is summarised in
Table 1. Immunoreactivity for AT100, which recognises
Alzheimer–type paired helical filament (PHF) tau, was
also demonstrated. NFTs and neuropil threads were also
identified using Gallyas silver staining further confirming
the presence of fibrillar tau.
Tau isoform determination
Immunohistochemial staining using isoform specific
antibodies demonstrated the expression of both 3- and
4-repeat tau isoforms. Immunoblotting of tau showed
a pattern similar to that of AD with the classical triplet
band of 3R- and 4R- tau isoforms compared to the 3R-
tau isoforms predominantly observed in PiD (Fig. 3).
BPAN and autophagy
In the mutation case and 3 controls LC3I and LC3II could
be demonstrated by immunoblotting confirming autopha-
gic activity (Fig. 4). As only a single case of WDR45 muta-
tion was available quantitation of immunoblots and
statistical analysis was not performed and clear alter-
ation of autophagic activity could not be demonstrated.
Discussion
We report the neuropathological details of a 51 year old
female with a clinical phenotype compatible with BPAN
and positive for the hemizygous loss-of-function mutation,
p.Leu232Alafs*53 in WDR45. This patient has previously
been reported in genetic studies as case HH8 [3, 5].
The major pathological findings were severe neuronal
loss with gliosis affecting the substantia nigra, iron depos-
ition in the substantia nigra and globus pallidus, axonal
swellings in the substantia nigra, gracile nucleus and cune-
ate nucleus together with very extensive phospho-tau de-
position similar to that previously been reported [5]. We
investigated the tau pathology, further characterising and
documenting the distribution and abundance of neuro-
fibrillary tangles, pre-tangles and neuropil threads. Fur-
thermore, we demonstrated that the tau protein was in
fibrillary conformation as structures were Gallyas silver
positive and AT100 immunoreactive and both 3-and 4-
repeat tau isoforms were represented similar to the tau
deposits of AD. This finding was confirmed by im-
munoblotting of insoluble tau which showed a pattern
similar to that of AD with the classical triplet band of
3R and 4R tau isoforms. This is a novel finding suggest-
ing that BPAN may be considered as a tauopathy and
further strengthening the link between tauopathies and
Fig. 3 Western blot of non-dephosphorylated sarkosyl-insoluble
brain fractions from Pick’s disease (PiD), Alzheimer’s disease (AD) and
the WDR45 mutation case which was run as duplicate samples. The
WDR45 case shows the classical triplet band as observed in AD cases
due to mixed 3R- and 4R-tau pathology
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other forms of NBIA such as PKAN, PLAN and MPAN
in which a degree of neurofibrillary tangle pathology is
a feature in some cases although extensive tau path-
ology is more often associated with PLAN [2, 10–13].
In neurodegenerative disorders, disruption of autophagy
inhibits elimination of abnormal and toxic protein ac-
cumulation and can promote cellular stress and death.
WDR45 belongs to a large family of WD40 repeat pro-
tein and is believed to be an important regulator of au-
tophagy as documented in yeast [14] and C. elegans
[15]. LC3-I is a soluble protein and conversion to LC3-
II occurs during activation of autophagy where LC3-II
is bound to the membrane of autophagosomes. An in-
crease in LC3-II levels may indicate an increase in au-
tophagy but also occurs where blockage in the final
steps in autophagy impairs autophagic flux. Increased
LC3-II and blockage of autophagic flux in lymphoblasts
from patients with WDR45 mutation has been demon-
strated implicating defective autophagy in the disease
pathogenesis [4]. Although our results relate to only
one patient and are therefore of a qualitative nature,
they support the concept that dysfunctional autophagy
is associated with WDR45 mutation. As autophagy is
known to contribute to the degradation of tau it seems
likely that impaired autophagy in BPAN may underlie
the severe tau pathology seen in this disease and sup-
ports the notion that autophagy may be important in
the pathogenesis of other forms of tauopathy [16].
Conclusion
We have described a case of BPAN and documented the
neuropathological changes confirming a characteristic
pattern of neuronal loss, most severe in the substantia
nigra with iron deposition in both the globus pallidus
and substantia nigra. Axonal swellings were present in
the substantia nigra, gracile nucleus and cuneate nu-
cleus. Impaired autophagic flux could not be demon-
strated in a single case however, this could be the basis
of future investigations. The striking widespread tau
deposition was shown for the first time to be composed
of fibrillar tau of Alzheimer-type and suggests that this
disease may be considered as a tauopathy.
Additional file
Additional file 1: Table S1. Primary and secondary antibodies used in
IHC stainings and western blot.
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